Literature DB >> 3022644

Effect of selenazofurin on influenza A and B virus infections of mice.

R W Sidwell, J H Huffman, E W Call, H Alaghamandan, P D Cook, R K Robins.   

Abstract

The inhibitory effects of selenazofurin and ribavirin on influenza A and B virus infections in mice were compared. Both compounds, when administered intraperitoneally (i.p.), reduced lung consolidation and prolonged mean day of death, but ribavirin more effectively increased survivor number and lowered lung viral hemagglutinin (HA) titers. Lung HA titers often increased in selenazofurin-treated animals. To determine the most appropriate i.p. treatment schedule, influenza A virus-infected mice were treated once, twice or thrice daily for 7-9 days, or once only. Treatment once daily for 9 days beginning 4 h pre-virus exposure, for 3 days beginning 24 h post-virus exposure, or once only 48 h post-virus exposure was most effective. Body temperature, which usually declined during infection, increased to near-normal levels in animals treated with selenazofurin, especially in animals treated a single time or for 3 days with high dose levels. Selenazofurin was well tolerated at a dose of 50 mg/kg administered twice daily, and at 400 mg/kg administered once only. Rectal temperatures temporarily declined following every other day treatment with 400 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3022644     DOI: 10.1016/0166-3542(86)90016-1

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Effect of intranasal administration of Lactobacillus casei Shirota on influenza virus infection of upper respiratory tract in mice.

Authors:  T Hori; J Kiyoshima; K Shida; H Yasui
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

Authors:  Michael P Malakhov; Laura M Aschenbrenner; Donald F Smee; Miles K Wandersee; Robert W Sidwell; Larisa V Gubareva; Vasiliy P Mishin; Frederick G Hayden; Do Hyong Kim; Alice Ing; Erin R Campbell; Mang Yu; Fang Fang
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.

Authors:  D B Mendel; C Y Tai; P A Escarpe; W Li; R W Sidwell; J H Huffman; C Sweet; K J Jakeman; J Merson; S A Lacy; W Lew; M A Williams; L Zhang; M S Chen; N Bischofberger; C U Kim
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.

Authors:  R W Sidwell; D F Smee; J H Huffman; D L Barnard; K W Bailey; J D Morrey; Y S Babu
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice.

Authors:  R W Sidwell; J H Huffman; K W Bailey; M H Wong; A Nimrod; A Panet
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

Review 6.  Prenatal stress: role in psychotic and depressive diseases.

Authors:  Julie A Markham; James I Koenig
Journal:  Psychopharmacology (Berl)       Date:  2010-10-15       Impact factor: 4.530

7.  Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice.

Authors:  R W Sidwell; J H Huffman; J Gilbert; B Moscon; G Pedersen; R Burger; R P Warren
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

8.  Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

Authors:  C Y Tai; P A Escarpe; R W Sidwell; M A Williams; W Lew; H Wu; C U Kim; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.